Analysts Have Conflicting Sentiments on These Healthcare Companies: Taysha Gene Therapies (TSHA) and Zimmer Biomet Holdings (ZBH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Taysha Gene Therapies (TSHA – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Taysha Gene Therapies (TSHA)
In a report released today, Gil Blum from Needham reiterated a Buy rating on Taysha Gene Therapies, with a price target of $10.00. The company’s shares closed last Monday at $4.53.
According to TipRanks.com, Blum is a 4-star analyst with an average return of
Currently, the analyst consensus on Taysha Gene Therapies is a Strong Buy with an average price target of $11.71, representing a 163.1% upside. In a report issued on February 18, Cantor Fitzgerald also maintained a Buy rating on the stock with a $19.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Zimmer Biomet Holdings (ZBH)
In a report released yesterday, Travis Steed from Bank of America Securities maintained a Hold rating on Zimmer Biomet Holdings, with a price target of $100.00. The company’s shares closed last Monday at $99.49, close to its 52-week low of $97.69.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Currently, the analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $101.06, representing a 3.8% upside. In a report issued on February 20, William Blair also initiated coverage with a Hold rating on the stock.
